News stories about Redhill Biopharma (NASDAQ:RDHL) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Redhill Biopharma earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.3316177763035 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern’s analysis:

Several brokerages recently issued reports on RDHL. Zacks Investment Research lowered shares of Redhill Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, November 24th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of Redhill Biopharma in a research report on Tuesday, November 21st. Roth Capital cut their target price on shares of Redhill Biopharma from $27.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, November 14th. Seaport Global Securities began coverage on shares of Redhill Biopharma in a research report on Friday, October 6th. They set a “buy” rating and a $19.00 target price for the company. Finally, UBS began coverage on shares of Redhill Biopharma in a research report on Wednesday, September 13th. They set a “reduce” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $21.10.

Redhill Biopharma (RDHL) opened at $5.03 on Thursday. Redhill Biopharma has a 12-month low of $4.82 and a 12-month high of $12.09.

ILLEGAL ACTIVITY WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/redhill-biopharma-rdhl-earning-somewhat-favorable-news-coverage-analysis-shows/1734526.html.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Insider Buying and Selling by Quarter for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.